<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="42104">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02558231</url>
  </required_header>
  <id_info>
    <org_study_id>AC-065A308</org_study_id>
    <nct_id>NCT02558231</nct_id>
  </id_info>
  <brief_title>The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension</brief_title>
  <acronym>TRITON</acronym>
  <official_title>The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension: A Multi-center, Double-blind, Placebo-controlled, Phase 3b Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Actelion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Actelion</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this clinical trial is to compare the efficacy and safety of an initial
      triple oral treatment regimen (macitentan, tadalafil, selexipag) versus an initial dual oral
      treatment regimen (macitentan, tadalafil, placebo) in newly diagnosed, treatment-naïve
      patients with pulmonary arterial hypertension.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pulmonary vascular resistance</measure>
    <time_frame>Baseline to Week 26</time_frame>
    <description>As measured by right heart catheterization</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>Triple oral combination treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Macitentan, tadalafil, and selexipag</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dual oral combination treatment</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Macitentan, tadalafil, and placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Macitentan</intervention_name>
    <description>Used open-label in both arms, 10 mg tablet, 1 tablet u.i.d.</description>
    <arm_group_label>Triple oral combination treatment</arm_group_label>
    <arm_group_label>Dual oral combination treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tadalafil</intervention_name>
    <description>Used open-label in both arms, 20 mg tablet, 1-2 tablets u.i.d.</description>
    <arm_group_label>Triple oral combination treatment</arm_group_label>
    <arm_group_label>Dual oral combination treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selexipag</intervention_name>
    <description>Used double-blind in the triple oral treatment arm, 200 microgram tablet, 1-8 tablets b.i.d.</description>
    <arm_group_label>Triple oral combination treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed informed consent prior to any study-mandated procedure.

          2. Male or female ≥ 18 and ≤ 75 years of age at screening.

          3. Initial PAH diagnosis &lt; 6 months prior to enrollment.

          4. RHC performed between Day −28 and Day 1, meeting all the following criteria:

               -  Mean pulmonary artery pressure (mPAP) ≥ 25 mmHg.

               -  Pulmonary artery wedge pressure or left ventricular end-diastolic pressure ≤ 15
                  mmHg.

               -  PVR ≥ 480 dyn•sec/cm5 (≥ 6 Wood Units).

               -  Negative vasoreactivity test mandatory in idiopathic, heritable, and drug/toxin
                  induced PAH (at this or a previous RHC).

          5. Symptomatic PAH belonging to one of the following subgroups:

               -  Idiopathic.

               -  Heritable.

               -  Drug or toxin induced.

               -  Associated with one of the following: connective tissue disease; HIV infection;
                  congenital heart disease.

          6. 6-minute walk distance (6MWD) ≥ 50 m at screening.

          7. Women of childbearing potential must not be pregnant, must perform regular pregnancy
             tests, and use reliable contraception.

        Exclusion Criteria:

          1. Any PAH-specific drug therapy at any time.

          2. Cardio pulmonary rehabilitation program based on exercise (planned, or started ≤ 12
             weeks prior to Day 1).

          3. Body mass index (BMI) &gt; 40 kg/m2 at screening.

          4. Presence of three or more of the following risk factors for heart failure with
             preserved ejection fraction at screening:

               -  BMI &gt; 30 kg/m2.

               -  Diabetes mellitus of any type.

               -  Essential hypertension.

               -  Coronary artery disease, i.e., any of the following:

                    -  History of stable angina or

                    -  More than 50% stenosis in a coronary artery (by coronary angiography) or

                    -  History of myocardial infarction or

                    -  History of or planned coronary artery bypass grafting and/or coronary
                       artery stenting.

          5. Acute myocardial infarction ≤ 12 weeks prior to screening.

          6. Stroke ≤ 12 weeks prior to screening.

          7. Known permanent atrial fibrillation.

          8. SBP &lt; 90 mmHg at screening or Day 1.

          9. Ongoing or planned treatment with organic nitrates and/or doxazosin.

         10. Presence of one or more of the following signs of relevant lung disease at any time
             up to screening:

               -  Diffusing capacity of the lung for carbon monoxide (DLCO) &lt; 40% of predicted
                  (eligible only if no or mild interstitial lung disease on computed tomography).

               -  Forced vital capacity (FVC) &lt; 60% of predicted.

               -  Forced expiratory volume in one second (FEV1) &lt; 60% of predicted.

         11. Known or suspected pulmonary veno-occlusive disease (PVOD).

         12. Documented severe hepatic impairment (with or without cirrhosis) according to
             National Cancer Institute organ dysfunction working group criteria, defined as total
             bilirubin &gt; 3 × upper limit of the normal range (ULN) accompanied by aspartate
             aminotransferase (AST) &gt; ULN (assessed by central laboratory at screening); and/or
             Child-Pugh Class C.

         13. Serum AST and/or alanine aminotransferase (ALT) &gt; 3 × ULN (assessed by central
             laboratory at screening).

         14. Severe renal impairment (estimated creatinine clearance ≤ 30 mL/min/1.73 m2) assessed
             by central laboratory at screening.

         15. Ongoing or planned dialysis.

         16. Hemoglobin &lt; 100 g/L assessed by central laboratory at screening.

         17. Known or suspected uncontrolled thyroid disease (hypo- or hyperthyroidism).

         18. Loss of vision in one or both eyes because of non-arteritic ischemic optic neuropathy
             (NAION).

         19. Treatment with strong inducers of cytochrome P450 3A4 (CYP3A4; e.g., carbamazepine,
             rifampin, rifampicin, rifabutin, rifapentin, phenobarbital, phenytoin, and St. John's
             wort) ≤ 28 days prior to Day 1.

         20. Treatment with strong inhibitors of CYP3A4 (e.g., ketoconazole, itraconazole,
             voriconazole, clarithromycin, telithromycin, nefazodone, ritonavir, and saquinavir) ≤
             28 days prior to Day 1.

         21. Treatment with another investigational drug (planned, or taken ≤ 12 weeks prior to
             Day 1).

         22. Hypersensitivity to any of the 3 study treatments or any excipient of their
             formulations.

         23. Pregnancy, breastfeeding, or intention to become pregnant during the study.

         24. Concomitant life-threatening disease with a life expectancy &lt; 12 months.

         25. Alcohol abuse.

         26. Any factor or condition likely to affect protocol compliance of the subject, as
             judged by the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Loic Perchenet</last_name>
    <email>loic.perchenet@actelion.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arizona Pulmonary Specialists, LTD</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>loic.perchenet@actelion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCSD Health Sciences</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>loic.perchenet@actelion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>loic.perchenet@actelion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Florida</name>
      <address>
        <city>Weston</city>
        <state>Florida</state>
        <zip>33331</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>loic.perchenet@actelion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Piedmont Pulmonary and Critical Care Research</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>loic.perchenet@actelion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals &amp; Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>loic.perchenet@actelion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kentuckiana Pulmonary Associates</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>loic.perchenet@actelion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111-1552</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>loic.perchenet@actelion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Boston University Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118-2526</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>loic.perchenet@actelion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Regents of the University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-5853</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>loic.perchenet@actelion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Michigan</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>loic.perchenet@actelion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Christ Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219-2906</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>loic.perchenet@actelion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UPMC Presbyterian</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>loic.perchenet@actelion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allegheny General Hospital of Research</name>
      <address>
        <city>Pittsburg</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>loic.perchenet@actelion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-8550</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>loic.perchenet@actelion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>loic.perchenet@actelion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Prince Albert Hospital</name>
      <address>
        <city>Camperdown, Sydney</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>loic.perchenet@actelion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Vincents Hospital Sydney</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>loic.perchenet@actelion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>LKH -Universität Klinkum Graz</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>loic.perchenet@actelion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Krankenhaus der Elisabethinen Linz</name>
      <address>
        <city>Linz</city>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>loic.perchenet@actelion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Erasme</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>loic.perchenet@actelion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Leuven - Campus Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>loic.perchenet@actelion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>loic.perchenet@actelion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre - Victoria Hospital</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>loic.perchenet@actelion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Toronto</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2N2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>loic.perchenet@actelion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>loic.perchenet@actelion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire de Cardiologie et de Pneumologie de Québec</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>loic.perchenet@actelion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Bicêtre</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <zip>94270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>loic.perchenet@actelion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Unversitätsklinikum Carl Gustav Carus</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>loic.perchenet@actelion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Giessen</name>
      <address>
        <city>Giessen</city>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>loic.perchenet@actelion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>loic.perchenet@actelion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>loic.perchenet@actelion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69126</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>loic.perchenet@actelion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Köln</name>
      <address>
        <city>Köln</city>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>loic.perchenet@actelion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Missionsärztliche Klinik Würzburg</name>
      <address>
        <city>Würzburg</city>
        <zip>97074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>loic.perchenet@actelion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Sant'Orsola</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>loic.perchenet@actelion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universiätsspital Zürich</name>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>loic.perchenet@actelion.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>September 15, 2016</lastchanged_date>
  <firstreceived_date>September 22, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tadalafil</mesh_term>
    <mesh_term>Selexipag</mesh_term>
    <mesh_term>Macitentan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
